|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.40 USD | +3.73% |
|
-14.08% | -13.68% |
| Capitalization | 929M 797M 742M 691M 1.29B 83.89B 1.39B 8.54B 3.36B 40.13B 3.49B 3.41B 147B | P/E ratio 2025 * |
37.6x | P/E ratio 2026 * | 12.4x |
|---|---|---|---|---|---|
| Enterprise value | 1.06B 909M 847M 788M 1.47B 95.66B 1.58B 9.73B 3.83B 45.76B 3.97B 3.89B 168B | EV / Sales 2025 * |
1.45x | EV / Sales 2026 * | 1.38x |
| Free-Float |
96.11% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Pacira BioSciences, Inc.
| 1 day | +3.43% | ||
| 1 week | -14.08% | ||
| Current month | -13.68% | ||
| 1 month | -16.26% | ||
| 3 months | -1.71% | ||
| 6 months | -4.16% | ||
| Current year | -13.68% |
| 1 week | 21.35 |  | 26.36 |
| 1 month | 21.35 | | 27.16 |
| Current year | 21.35 | | 26.81 |
| 1 year | 19.84 | | 27.64 |
| 3 years | 11.16 | | 48.6 |
| 5 years | 11.16 | | 82.16 |
| 10 years | 11.16 | | 82.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frank Lee
CEO | Chief Executive Officer | 58 | 2024-01-01 |
Shawn Cross
DFI | Director of Finance/CFO | 58 | 2024-10-20 |
Anthony Molloy
CMP | Compliance Officer | 52 | - |
| Director | Title | Age | Since |
|---|---|---|---|
Laura Brege
CHM | Chairman | 68 | 2025-01-27 |
Mark Kronenfeld
BRD | Director/Board Member | 71 | 2013-06-11 |
Mark Froimson
BRD | Director/Board Member | 65 | 2017-06-14 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +3.86% | 0.24% | 22 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +3.73% | -14.08% | +8.71% | -41.13% | 929M | |
| -0.35% | -3.19% | +44.00% | +199.85% | 964B | |
| +1.97% | +5.27% | +50.89% | +26.72% | 515B | |
| +1.04% | -4.90% | +26.45% | +45.25% | 390B | |
| +0.94% | +4.30% | +29.90% | +17.96% | 363B | |
| +2.41% | +2.19% | +32.56% | +23.08% | 292B | |
| +2.13% | +4.07% | +27.83% | +37.35% | 272B | |
| +2.35% | +2.13% | +11.30% | +0.42% | 269B | |
| -1.32% | +3.90% | -38.31% | -19.23% | 265B | |
| +1.18% | -4.07% | +22.70% | +21.65% | 175B | |
| Average | +1.30% | -0.25% | +21.61% | +31.19% | 350.6B | |
| Weighted average by Cap. | +0.85% | +1.56% | +29.59% | +70.26% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 732M 628M 584M 544M 1.01B 66.04B 1.09B 6.72B 2.64B 31.59B 2.74B 2.69B 116B | 792M 680M 633M 589M 1.1B 71.52B 1.18B 7.28B 2.86B 34.21B 2.97B 2.91B 125B |
| Net income | 25.41M 21.81M 20.3M 18.89M 35.26M 2.29B 38.01M 233M 91.83M 1.1B 95.31M 93.34M 4.02B | 77.23M 66.28M 61.71M 57.42M 107M 6.97B 116M 709M 279M 3.34B 290M 284M 12.22B |
| Net Debt | 130M 112M 104M 96.94M 181M 11.77B 195M 1.2B 471M 5.63B 489M 479M 20.63B | 162M 139M 130M 121M 225M 14.64B 243M 1.49B 586M 7B 608M 596M 25.66B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-14 | 22.40 $ | +3.73% | 633,144 |
| 26-01-13 | 21.60 $ | -5.80% | 990,121 |
| 26-01-12 | 22.93 $ | -2.55% | 665,862 |
| 26-01-09 | 23.53 $ | -9.57% | 2,441,305 |
| 26-01-08 | 26.02 $ | +0.08% | 823,300 |
Delayed Quote Nasdaq, January 14, 2026 at 03:52 pm EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- PCRX Stock
Select your edition
All financial news and data tailored to specific country editions
